This page shows the latest tenapanor news and features for those working in and with pharma, biotech and healthcare.
Tenapanor also achieved a 22%-24% reduction in levels of FGF23, a biomarker linked to an elevated risk of cardiovascular complications in CKD patients, compared to control. ... thinks tenapanor is “poised to be one of biotech's great product launches
The two firms have been working on the NHE3 inhibitor tenapanor since 2012. ... which are conditions where we believe tenapanor could potentially transform the treatment paradigm," he said.
More from news
Approximately 2 fully matching, plus 0 partially matching documents found.
We live in a hyper-connected world. This has clear benefits for the health of our communities, our businesses and our...